In order to achieve specific targeting towards HER2 in breast cancer, cetuximab monoclonal antibody was either covalently [148] or non-covalently [149] coupled to liposomes, by utilizing the affinity between the binding protein coupled to cetuximab and liposomes. Here, ERBB2 is linked to breast cancer.